Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proactive Fecal Calprotectin Home Monitoring in Ulcerative Colitis: Results of a Prospective Randomized Control Trial.

Gastroenterology·2026
Same author

Development and Validation of a Large Language Model Case Identification Strategy for Eosinophilic Esophagitis.

Gastro hep advances·2026
Same author

Glucuronidation metabolomic fingerprinting to map host-microbe metabolism.

Nature communications·2026
Same author

Prevalence of inflammatory bowel disease across states: estimates based on claims database.

Inflammatory bowel diseases·2026
Same author

Comparative effectiveness of low versus high dose upadacitinib as maintenance treatment in patients with ulcerative colitis: a real-world cohort study from the United States.

Crohn's & colitis 360·2026
Same author

Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial.

Journal of Crohn's & colitis·2026
Same journal

Understanding Celiac Disease From Genetics to the Future Diagnostic Strategies.

Clinical medicine insights. Gastroenterology·2023
Same journal

Hepatitis B screening compliance and non-compliance among Chinese, Koreans, Vietnamese and Cambodians.

Clinical medicine insights. Gastroenterology·2019
Same journal

Biodegradable Stents in Resistant Peptic Oesophageal Stricture: Is It the Right Way to Go?

Clinical medicine insights. Gastroenterology·2019
Same journal

Melanosis Coli: A Helpful Contrast Effect or a Harmful Pigmentation?

Clinical medicine insights. Gastroenterology·2018
Same journal

Understanding Therapeutic Concepts in Crohn's Disease.

Clinical medicine insights. Gastroenterology·2018
Same journal

The Benefits of Neuromuscular Electrical Stimulation in the Muscular and Functional Capacity of Patients With Liver Cirrhosis: Protocol for a Randomized Clinical Trial.

Clinical medicine insights. Gastroenterology·2018
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Microscopic colitis and Medication Use.

Monina F Pascua1, Prashant Kedia, Mark G Weiner

  • 1Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

Clinical Medicine Insights. Gastroenterology
|July 20, 2010
PubMed
Summary
This summary is machine-generated.

This study found no increased association between microscopic colitis (MC) and commonly prescribed drugs like proton pump inhibitors (PPIs), statins, or SSRIs, despite prior suggestions of a link.

More Related Videos

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Related Experiment Videos

Last Updated: Jun 10, 2026

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
09:01

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice

Published on: March 10, 2015

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Epidemiology

Background:

  • Microscopic colitis (MC) incidence is rising, but its cause is unknown.
  • Commonly prescribed medications are suspected triggers for MC.
  • Previous studies suggested a link between MC and certain drugs.

Purpose of the Study:

  • To investigate the prevalence of proton pump inhibitor (PPI), HMG-CoA reductase inhibitor (statin), and selective serotonin reuptake inhibitor (SSRI) use in MC patients.
  • To compare medication use in MC patients against random and diarrhea control groups.
  • To evaluate the potential etiological role of these medications in MC.

Main Methods:

  • Retrospective study of primary care patients (2002-2007).
  • Identified 26 MC cases (biopsy-proven lymphocytic or collagenous colitis).
  • Compared medication use within 12 months prior to diagnosis against 259 random controls and 259 diarrhea controls.

Main Results:

  • No increased odds ratios (ORs) for PPI, SSRI, or statin use in MC patients compared to diarrhea controls.
  • Proton pump inhibitor (PPI) and statin use was lower in MC patients than in random controls (p<0.05).
  • Adjusted ORs for PPI, SSRI, and statin were 0.28, 0.87, and 1.12, respectively.

Conclusions:

  • This study did not find an association between MC and the use of PPIs, statins, or SSRIs.
  • Findings contradict previous suggestions of an etiological link between these medications and MC.
  • Further research may be needed to explore other potential triggers for microscopic colitis.